SNS-595 AND METHODS OF USING THE SAME

1 - 25 . (canceled)

26 . A method for treating cancer comprising administering to a human patient having cancer (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in a dose of about 10 mg/m 2 -100 mg/m 2 and a therapeutically effective amount of a second agent selected from an agent that inhibits nonhomologous end joining repair, an apoptosis enhancing agent, an alkylating agent, an anti-neoplastic antibiotic, a platinum coordination complex and a topoisomerase II inhibitor.

27 . The method of claim 26 , wherein the dose is about 30 mg/m 2 -75 mg/m 2 .

28 . The method of claim 26 , wherein the dose is about 40 mg/m 2 -80 mg/m 2 .

29 . The method of claim 26 , wherein the dose is about 50 mg/m 2 -90 mg/m 2 .

30 . The method of claim 26 , wherein the second agent is the agent that inhibits nonhomologous endjoining repair which is a DNA-PK inhibitor.

31 . The method of claim 26 , wherein the second agent is the agent that inhibits nonhomologous endjoining repair which is a ligase IV inhibitor.

32 . The method of claim 26 , wherein the second agent is the apoptosis enhancing agent which is a caspase-9 activator, a caspase-3 activator or a Hsp90 inhibitor.

33 . The method of claim 26 , wherein the second agent is the alkylating agent is which is a nitrogen mustard, an alkyl sulfonate, a nitrosourea, or a triazene

34 . The method of claim 26 , wherein the second agent is the anti-neoplastic antibiotic which is bleomycin, dactinomycin, daunorubicin or doxorubicin.

35 . The method of claim 26 , wherein the second agent is the platinum coordination complex which is carboplatin, cisplatin or oxaliplatin.

36 . The method of claim 26 , wherein the cancer is leukemia.